Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
antisense-pharma.com

See what CB Insights has to offer

Founded Year

1998

Stage

Series A | Alive

Total Raised

$11.6M

Last Raised

$11.6M | 10 yrs ago

About Antisense Pharma

Antisense Pharma is a biopharmaceutical company committed to researching, developing and marketing drugs that enable targeted treatment of aggressive tumor diseases. The company's main objective is to extend the life expectancy of patients considerably and, at the same time, improve quality of life.

Antisense Pharma Headquarter Location

Josef-Engert-Strasse 9

93053,

Germany

Latest Antisense Pharma News

Germany’s Antisense Pharma Closes On About $11M In Financing

Jul 6, 2011

Germany’s Antisense Pharma Closes On About $11M In Financing July 6, 2011 By Mark Boslet Antisense Pharma said Wednesday that MIG Funds 2, 3 and 9 as well as GAF have ponied up a new round of financing worth about $11 million, or about 8 million euros. The German bio-pharmaceutical startup also said its founder and chief executive, Karl-Hermann Schlingensiepen, will leave his operational role and join the supervisory board, in addition to focus on strategy as a consultant PRESS RELEASE Antisense Pharma completes round of financing worth approximately 8 million euro – Founding shareholders facilitate the participation of new investors Effective July, 2011, Antisense Pharma’s founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company’s strategy as a consultant. The biopharmaceuticalcompany Antisense Pharma announced today that MIG Funds 2, 3 and 9 as well as GAF have increased their share capital by approximately 8 million euro. In addition, the current Chief Execute Officer (CEO), Dr. Karl-Hermann Schlingensiepen changed from the operative management of Antisense Pharma to a strategic advisory position closely associated with the company as of July 1. Dr. Karl-Hermann Schlingensiepen and the investors developed this solution together. Pivotal phase II/III study on pancreatic cancer: Start of a second international clinical trial of Antisense Pharma in preparation “With this major entry into the systemic, intravenous application in solid tumors, we share Antisense Pharma’s hope that trabedersen could become the first medication approved for second-line therapy of pancreatic cancer,” says Michael Motschmann, Chief Executive of MIG Verwaltungs AG. “Trabedersen could give new hope to patients suffering from this extremely aggressive type of cancer and open up a greatly needed but thus far completely vacant market niche along with its corresponding high revenue potential. At the same time, this means a risk reduction for the development of trabedersen, as this medication now has several marketing opportunities if the trials are successful. Furthermore, there is a potential for added value since new markets can be opened up.” © 2015 Buyouts Insider / Argosy Group LLC

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Antisense Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Antisense Pharma is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,880 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Antisense Pharma Patents

Antisense Pharma has filed 10 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/10/2011

1/20/2015

Molecular biology, Drug delivery devices, Biotechnology, Dosage forms, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/10/2011

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/20/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Drug delivery devices, Biotechnology, Dosage forms, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.